1 / 37

Locally advanced and metastatic disease

Locally advanced and metastatic disease. Eribulin mesylate (E7389): review of efficacy and tolerability. Jennifer Foglietta Ospedale Santa Maria della Misericordia Perugia.

ziazan
Télécharger la présentation

Locally advanced and metastatic disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Locally advanced and metastatic disease Eribulin mesylate (E7389): review of efficacy and tolerability Jennifer Foglietta Ospedale Santa Maria della Misericordia Perugia

  2. - Indications- Structure of molecule- Mechanism of action- Clinical trials (phase II and III) - efficacy outcomes - safety Eribulin mesylate (E7389)

  3. Indications of eribulin Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

  4. Eribulin: structure of molecule - Synthetic analogue of halichondrin B; natural product from marine sponge Halichondriaokadai - Tubulin-targeting agent - Eribulin could be effective in patients with disease that is resistant to other tubulin-targeting-agents Halichondria okadai Jordan MA, et al. Mol Cancer Ther. 2005;4:1086-1095.

  5. Mechanism of action Polimerizzazione tubulina 1 Eribulin Blocks microtubule polymerization 3 Growth of microtubules • Sequesters tubulin into non functional aggregates Spindle Pole Eribulin Eribulin Eribulin No effect on depolymerization 2 Shortening of microtubules Eribulin Jordan MA, et al. Mol Cancer Ther. 2005;4:1086-1095. Jordan MA et al. Current Cancer Drug Targets. 2007; 7:730-742.

  6. Different sites of action Paclitaxel, docetaxel e epothilone B Eribulina Vinblastina • Eribulina lega solo all’estremità in crescita, (+) ends • Legano le subunitàβall’internodeimicrotubuli • Si lega lungo il lato esterno e lega le (+) ends • Inibiscono l’allungamento e l’accorciamento dei microtubuli • Inibisce solo l’allungamento Modified from Jordan MA and Wilson L. Nat Rev Cancer. 2004; 4:253-265. and Smith J. Biochemistry. 2010; 49:1331-1337.

  7. Phase II trials

  8. Study 201: trial design Vahdat LT, et al. J Clin Oncol. 2009;27:2954-2961. • Patients (N=103) • Advanced breast cancer • Prior anthracyclineand taxane • Progression <6 months of last chemotherapy • ECOG PS: 0-1 • Pre-existing neuropathy Grade ≤2 Eribulin mesylate 1.4 mg/m2 administered by IV for up to 5 min 28-day cohort (n=70) Initial schedule Dosing days1, 8, and 15q28 days Alternative schedule 21-day cohort(n=33) Days 1, 8 q21 days Neutropenia day 15

  9. Study 211: trial design • Patients (N=299) • Advanced breast cancer • Prior anthracycline, taxane, capecitabine • Progression on or within 6 months of last chemotherapy • ECOG PS: 0-2 • Pre-existing neuropathy Grade <2 • Primary endpoint • ORR by IRR • Other endpoints • Duration of response • ORR by investigator • PFS, OS • EORTC QoL • Safety Eribulinmesylate 1.4 mg/m2 2-5 minute IV Days 1,8 q21 days Cortes J, et al. J ClinOncol 2010;28:3922–3928.

  10. Phase II trials: 201 and 211 study • ORR: 11.5% • Median DOR: 5.6 months • Median PFS: 2.6 months • 6-month PFS 25.9% [95% CI, 15.5, 36.3] • Median OS: 9 months (range 15–826 days) • 6-month survival 67.8% [95% CI, 58.0, 77.6) • 1-year survival 45.7% [95% CI, 35.2, 56.2] 201 Study1 (n = 103): Prior taxane & anthracycline* • Primary Endpoint: • ORR with independent review Secondary Endpoints: • DOR, PFS, OS, Adverse events • ORR: 9.3% • Median DOR: 4.1 months • Median PFS: 2.6 months • 6-month PFS 15.6% (95% CI, 10.7, 20.5) • Median OS: 10.4 months • 6-month survival 72.3% (95% CI, 66.9, 77.6) • 1-year survival 45.7% [95% CI, 35.2, 56.2] 211 Study2 (n = 299): Prior taxane, anthracycline, & capecitabine* ORR, overall response rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival *MBC patients with progression of disease ≤6 months of last chemotherapy and, if present, preexisting neuropathy ≤ grade 2 1. Vahdat L, et al. J ClinOncol. 2009;27:2954-2961. 2. Cortes J, et al. J ClinOncol. 2010;28:3922-3928.

  11. Safety: Hematologic adverse events Cortes J, et al. J ClinOncol. 2010;28:3922-3928 Vahdat L, et al. J ClinOncol. 2009;27:2954-2961

  12. Safety: Not hematologic adverse events Cortes J, et al. J ClinOncol. 2010;28:3922-3928 Vahdat L, et al. J ClinOncol. 2009;27:2954-2961

  13. Eribulin+trastuzumabas first line MBC:trial design Vahdat L et al. SABCS2012 poster P5-20-04

  14. Eribulin+trastuzumab: characteristics of patients Vahdat L et al. SABCS2012 poster P5-20-04

  15. Eribulin+trastuzumab: primaryoutcome Vahdat L et al. SABCS2012 poster P5-20-04

  16. Eribulin+trastuzumab:Secondaryefficacyoutcomes Final results are expected by December 2013 Vahdat L et al. SABCS2012 poster P5-20-04

  17. Eribulin+trastuzumab:safety Vahdat L et al. SABCS2012 poster P5-20-04

  18. Phase III trials

  19. EMBRACE: Physician’s Choice (TPC) vs Eribulin • Patients (n=762) • Locally recurrent or MBC • 2–5 prior chemotherapies • ≥ 2 for advanced disease • Prior anthracycline and taxane • Progression ≤ 6 months of last chemotherapy • Neuropathy ≤ grade 2 • ECOG ≤ 2 • Primary Endpoint: • OS Secondary Endpoints: • PFS • ORR • Safety Eribulinmesylate (n=508) 1.4 mg/m2* IV over 2-5 minutes on Day 1,8 q21 days RANDOMISATION 2:1 • TPC (n=254): • Any monotherapy (cytotoxic, hormonal, biological); or • Palliative treatment; or • Radiotherapy • Stratification: • Geographical region • Prior capecitabine • HER2 status • *Equivalent to 1.23 mg/m2eribulin • Exploratory subgroups: Hormone receptor expression status (ER, PgR, HER2, triple-negative); number of organs involved; sites of disease Cortes J, et al. Lancet 2011;377:914-923.

  20. EMBRACE: main characteristics of patients Cortes J, et al. Lancet 2011;377:914-923.

  21. EMBRACE: Priorantitumourtherapies Cortes J, et al. Lancet 2011;377:914-923.

  22. EMBRACE: TPC 96% pts treated with chemotherapy Total patients = 247 N= 61 N= 46 % of Patients N= 44 N= 38 N= 25 N= 24 N= 9 None of patientsreceivedonlysupportive care or immunotherapy **Include: paclitaxel, docetaxel, abraxane, (ixabepilone) Cortes J, et al. Lancet 2011;377:914-923.

  23. EMBRACE: Overall Survival Eribulin TPC p-value= 0.041 HR (95CI) = 0.81 Cortes J, et al. Lancet 2011;377:914-923.

  24. 1-year survival Eribulin (n=508) 54.5% TPC (n=254) 42.8% EMBRACE: OS (ITT Population) Updated 3 March 2010 1.0 0.8 EribulinMedian 13.2 months 0.6 HR* 0.81 (95% CI 0.68, 0.96)Nominal p value=0.014 Overall survival (%) TPCMedian 10.6 months 0.4 0.2 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 Time (months)

  25. EMBRACE: Overall Survival by Stratification Factor* HER2, human epidermal growth factor receptor type 2.*Intent-to-treat population; Based upon a stratified Cox analysis including geographic region, HER-2/neu status, and prior capecitabine therapy as strata. Cortes J, et al. Lancet 2011;377:914-923.

  26. EMBRACE: secondary endpoint PFS Cortes J, et al. Lancet 2011;377:914-923.

  27. EMBRACE: secondary endpoint ORR Cortes J, et al. Lancet 2011;377:914-923.

  28. EMBRACE: safety Cortes J, et al. Lancet 2011;377:914-923.

  29. Embrace: hematologic adverse events Cortes J, et al. Lancet 2011;377:914-923.

  30. Embrace: not hematologic adverse events Cortes J, et al. Lancet 2011;377:914-923.

  31. Study 301: eribulin vs capecitabinetrialdesign * Stratification: - geographicregion - HER2 status Co-primary end-points: OS and PFS Secondaryendpoints: ORR, QoL, DOR, 1-, 2-, 3-year survival and safety * ≤ 2 for advanceddisease Kaufman PA et al. SABCS 2012 S6-6

  32. Study 301: eribulin vs capecitabinecharacteristics of patients Kaufman PA et al. SABCS 2012 S6-6

  33. Study 301: eribulin vs capecitabine Co-primaryendpoints Kaufman PA et al. SABCS 2012 S6-6

  34. Study 301: eribulin vs capecitabine OS Pre-specifiedSubgroup Analysis Author conclusions: “particular patient subgroups may have greater therapeutic benefit with eribulin and this may warrant further study” Kaufman PA et al. SABCS 2012 S6-6

  35. Study 301: eribulin vs capecitabine Response Rate Kaufman PA et al. SABCS 2012 S6-6

  36. Study 301: eribulin vs capecitabine Toxicity Kaufman PA et al. SABCS 2012 S6-6

  37. Conclusions • Efficacy of eribulin in MBC pts • Combination with other agents? • Manageable toxicity • Common EAs: neutropenia, fatigue, neuropathy • Low incidence of neuropathy grade 3/4 • Trials ongoing in early breast cancer (adjuvant and neoadjuvant setting) • Trials in other solid tumours (sarcoma, NSCLC, pancreatic cancer…)?

More Related